Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu + Tumors
Authors:
- 1 April 2001
- journal article
- research article
- Published by SAGE Publications in Journal of Hematotherapy & Stem Cell Research
- Vol. 10 (2) , 247-260
Abstract
Relapse after adjuvant chemotherapy or high-dose chemotherapy with stem cell transplant for high-risk breast cancer remains high and new strategies that provide additional antitumor effects are needed. This report describes methods to generate highly effective HER2/neu-specific cytotoxic T cells by arming activated T cells with anti-CD3 × anti-HER2/neu bispecific antibody (BsAb). OKT3 and 9184 (anti-HER2) monoclonal antibodies (mAb) were conjugated and used to arm T cells that were subsequently tested in binding, cytotoxicity, and cytokine secretion assays. Armed T cells aggregated and specifically killed HER2/neu+ breast cancer cells. Cytotoxicity emerged after 6 days of culture, was higher in armed T cells than unarmed T cells at all effector to target ratios (E/T) tested, and increased as the arming dose was increased. At an E/T of 20:1, the mean cytotoxicity of armed activated T cells (ATC) from 10 normal subjects increased by 59 ± 11% (±SD) over that seen in unarmed ATC (p < 0.001) and the mean cytotoxicity of armed ATC from 6 cancer patients increased by 32 ± 9% above that seen for unarmed ATC (p < 0.0004). After arming, the BsAb persisted on ATC up to 72 h and armed ATC continued to be cytotoxic up to 54 h. The amount of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted was 1699, 922, and 3092 pg/ml/106 cells per 24 h, respectively, when armed T cells were exposed to a HER2/neu+ breast carcinoma cell line. These studies show the feasibility and clinical adaptability of this approach for generating large numbers of anti-HER2-specific, cytotoxic T cells for clinical trials.Keywords
This publication has 31 references indexed in Scilit:
- Bispecific antibodies for treatment of cancer in experimental animal models and manAdvanced Drug Delivery Reviews, 1998
- Release of Cytokines and Soluble Cell Surface Molecules by PBMC after Activation with the Bispecific Antibody CD3 × CD19Scandinavian Journal of Immunology, 1997
- Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal AntibodyJNCI: Journal of the National Cancer Institute, 1995
- Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cellsInternational Journal of Cancer, 1995
- Bispecific monoclonal antibody anti‐CD3 X anti‐tenascin: An immunotherapeutic agent for human gliomaInternational Journal of Cancer, 1995
- T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition?Immunology Today, 1994
- CD30‐antigen‐specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of hodgkin's lymphomaInternational Journal of Cancer, 1993
- Optimization of culture conditions for activation and large‐scale expansion of human T lymphocytes for bispecific antibody‐directed cellular immunotherapyInternational Journal of Cancer, 1992
- Signal transduction by receptors with tyrosine kinase activityCell, 1990
- Induction of tumor‐cell lysis by bi‐specific monoclonal antibodies recognizing renal‐cell carcinoma and cd3 antigenInternational Journal of Cancer, 1989